Needham Maintains Buy on MapLight Therapeutics, Raises Price Target to $42
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $37 to $42.
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $37 to $42.